5 Key Takeaways

• 1

  The diagnostics landscape for advanced breast cancer is evolving due to targeted therapies for ESR1-mutation-positive disease.

• 2

  New oral SERD therapies have received regulatory approval, prompting laboratories to choose economically sustainable testing platforms.

• 3

  Liquid biopsy tests for ESR1 mutations face accessibility challenges due to centralized testing models and high costs.

• 4

  Digital PCR technology offers cost-effective, sensitive detection of ESR1 mutations compared to next-generation sequencing.

• 5

  IHC is not suitable for resistance monitoring in ESR1 mutations, while ddPCR provides precise quantification of these mutations.